Immunocore Holdings (IMCR) Invested Capital (2019 - 2024)

Immunocore Holdings (IMCR) has reported Invested Capital for 6 consecutive years, with $48.2 million the latest figure, recorded in Q3 2024.

• Quarterly Invested Capital changed N/A year-over-year to $48.2 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $48.2 million (changed N/A YoY) and the FY2022 annual result came in at $160.5 million, up 67.59% from the prior year.
• Invested Capital advanced to $48.2 million in Q3 2024 per IMCR's latest filing, from $1.2 million in the prior quarter.
• Over the last five years, Invested Capital for IMCR reached as high as $160.5 million in Q4 2022 and fell as low as $1.2 million in Q2 2023.
• A 5-year average of $70.4 million and a median of $48.4 million in 2020 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2020 — Invested Capital slumped 41.67% — and 2021, when it jumped 93.9%.
• Year by year, Invested Capital stood at $48.4 million in 2020, then soared by 93.9% to $93.8 million in 2021, then jumped by 71.06% to $160.5 million in 2022, then tumbled by 99.23% to $1.2 million in 2023, then soared by 3787.35% to $48.2 million in 2024.
• According to Business Quant data, Invested Capital over the past three periods registered $48.2 million, $1.2 million, and $160.5 million for Q3 2024, Q2 2023, and Q4 2022 respectively.